The development and spread of antibiotic resistance in bacteria is a universal threat to both humans and animals. New therapies against multidrug resistant infections are urgently needed. The majority of currently available antibiotics have low efficacy against Gram-negative pathogens because of active efflux of drugs from cells by multidrug efflux transporters. These transporters are promising targets in development of small molecule efflux inhibitors (EPIs) that could be used in combinations with antibiotics to improve their efficacy against Gram-negative pathogens. Our long-term goal is to understand the molecular mechanism of drug efflux in Gram-negative bacteria and to develop approaches to inhibit multidrug efflux transporters. During the previous funding period, using a combination of biochemical, genetic and biophysical approaches we have reconstructed a sequence of events leading to the assembly of active drug efflux complexes and characterized the roles of each component in this process. Our findings exposed a previously unknown vulnerability of multidrug pumps that could be targeted in development of new inhibitors. The objective of this application is to characterize this vulnerability in molecular details and to discover new effectiv inhibitors of drug efflux in Gram-negative bacteria. The central hypothesis is that periplasmic membrane fusion proteins control the transition in efflux pumps from the dormant to the active state, and that inhibition of this transition is an effective way to block multidrug efflux in Gram negative pathogens. The experimental approach is based on molecular analyses of biochemical properties of efflux complexes in the presence of EPIs and the rational design of new inhibitors. We will pursue three specific aims: (i) to investigate the activation of multidrug efflux pumps;(i) to investigate the mechanisms of drug efflux inhibition;(iii) to identify new allosteric inhibitor of drug efflux transporters. The expected outcome of the proposed studies is detailed understanding of how multidrug efflux pumps are activated and new allosteric EPIs acting on this critical step in drug efflux. This contribution is significant because EPIs are expected to restore activities of already existing antibiotics and expand therapeutic options against multidrug resistant infections.
Infections caused by Gram-negative pathogens are notoriously difficult to treat with antibiotics. The major cause of multiple antibiotic resistance n clinical isolates is active efflux of antibiotics from cells. The proposal is focused on understanding the molecular mechanism of multidrug efflux and finding effective means to inhibit this mechanism.
|Hwang, Hyea; Paracini, Nicolò; Parks, Jerry M et al. (2018) Distribution of mechanical stress in the Escherichia coli cell envelope. Biochim Biophys Acta Biomembr 1860:2566-2575|
|Picard, Martin; Tikhonova, Elena B; Broutin, Isabelle et al. (2018) Biochemical Reconstitution and Characterization of Multicomponent Drug Efflux Transporters. Methods Mol Biol 1700:113-145|
|Zgurskaya, Helen I; Rybenkov, Valentin V; Krishnamoorthy, Ganesh et al. (2018) Trans-envelope multidrug efflux pumps of Gram-negative bacteria and their synergism with the outer membrane barrier. Res Microbiol 169:351-356|
|Amaro, Rommie E; Baudry, Jerome; Chodera, John et al. (2018) Ensemble Docking in Drug Discovery. Biophys J 114:2271-2278|
|López, Cesar A; Travers, Timothy; Pos, Klaas M et al. (2017) Dynamics of Intact MexAB-OprM Efflux Pump: Focusing on the MexA-OprM Interface. Sci Rep 7:16521|
|Yue, Zhi; Chen, Wei; Zgurskaya, Helen I et al. (2017) Constant pH Molecular Dynamics Reveals How Proton Release Drives the Conformational Transition of a Transmembrane Efflux Pump. J Chem Theory Comput 13:6405-6414|
|Haynes, Keith M; Abdali, Narges; Jhawar, Varsha et al. (2017) Identification and Structure-Activity Relationships of Novel Compounds that Potentiate the Activities of Antibiotics in Escherichia coli. J Med Chem 60:6205-6219|
|Abdali, Narges; Parks, Jerry M; Haynes, Keith M et al. (2017) Reviving Antibiotics: Efflux Pump Inhibitors That Interact with AcrA, a Membrane Fusion Protein of the AcrAB-TolC Multidrug Efflux Pump. ACS Infect Dis 3:89-98|
|Ntreh, Abigail T; Weeks, Jon W; Nickels, Logan M et al. (2016) Opening the Channel: the Two Functional Interfaces of Pseudomonas aeruginosa OpmH with the Triclosan Efflux Pump TriABC. J Bacteriol 198:3176-3185|
|Weeks, Jon W; Nickels, Logan M; Ntreh, Abigail T et al. (2015) Non-equivalent roles of two periplasmic subunits in the function and assembly of triclosan pump TriABC from Pseudomonas aeruginosa. Mol Microbiol 98:343-56|
Showing the most recent 10 out of 34 publications